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Abstract (250 words):  32 
Nestorone® (NES) is a highly potent non-androgenic progestin being developed for 33 
contraception. NES is a synthetic progestin that may possess neuroprotective and myelin 34 
regenerative potential as an added health benefits. In receptor transactivation experiments, 35 
NES displayed greater potency than progesterone to transactivate the human progesterone 36 
receptor (hPR). This was confirmed by docking experiments which revealed that NES adopts 37 
the same docking position within the PR ligand-binding domain (LBD) as progesterone and 38 
forms additional stabilizing contacts between 17α-acetoxy and 16-methylene groups and PR 39 
LBD supporting its higher potency than progesterone. The analogue 13-ethyl NES also 40 
establishes similar contacts as NES with Met909, leading to comparable potency as NES. In 41 
contrast, NES is not stabilized within the human androgen receptor (hAR)-LBD leading to 42 
negligible AR transactivation. Since progesterone acts in the brain by both PR-binding and 43 
indirectly via the metabolite allopregnanolone binding to GABAA receptor (GABAAR), we 44 
investigated if NES is metabolized to 3α, 5α-tetrahydronestorone (3α, 5α-THNES) in the brain 45 
and if this metabolite could interact with GABAAR. In female mice, low concentrations of 46 
reduced NES metabolites were identified by Gas Chromatography-Mass Spectrometry in both 47 
plasma and brain. However, electrophysiological studies showed that 3α, 5α-THNES exhibited 48 
only limited activity to enhance GABAAR-evoked responses with WSS-1 cells and did not 49 
modulate synaptic GABAARs of mouse cortical neurons. Thus the inability of reduced metabolite 50 
of NES (3α, 5α-THNES) to activate GABAAR suggests that the neuroprotective and myelin 51 
regenerative effects of NES are mediated via PR binding and not via its interaction with the 52 
GABAAR. 53 
Introduction: 54 
NES (16-methylene-17α-acetoxy-19-nor-pregn-4-ene-3, 20-dione, also known as ST1435), 55 
belongs to the group of “19-nor pregnanes” (1, 2). It has been evaluated as a contraceptive 56 
agent and is also being considered as a potential progestin for use in HRT. NES has been 57 
synthesized with the objective of creating a highly specific progestin, with selective binding to 58 
the progesterone receptor (PR). NES exerts potent progestational and antiestrogenic actions on 59 
the uterus and does not interact with estrogen, or androgen receptors (1, 3).  NES is inactive 60 
when given orally to humans or animals (4 - 7) but is very potent when delivered parenterally, 61 
with a progestational activity 100 times higher than that of progesterone (1, 3). Low doses of 62 
NES have been found to be very effective in preventing ovulation, allowing its development as a 63 
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contraceptive in humans in different non-oral delivery systems such as silastic implants, vaginal 64 
ring and transdermal gel (8 - 11).  65 
Synthetic steroidal progestins are structurally related to either testosterone and characterized by 66 
a 17-hydroxyl group (e.g. norethindrone and levonorgestrel), or to the natural hormone 67 
progesterone (P) and harbor a 17β-methyl ketone function (e.g. NES). They act by binding to 68 
and transactivating the progesterone receptor (PR), a transcription factor belonging to the 69 
nuclear receptor superfamily. 70 
Since different progestins differ in their progestational and anti-estrogenic activity, we used 71 
different approaches to assess the progestational activity of NES, as well as its lack of 72 
androgenic effect as compared to levonorgestrel (LNG). In previous experiments we showed 73 
that NES was active in stimulating neuroprotection and neuroregeneration (12, 13) and myelin 74 
repair (14 - 16) and these effects were shown to be exerted via the PR (13, 17). However, we 75 
wanted to determine whether part of this neuro-regenerative activity could be mediated via one 76 
of the reduced metabolites of NES as  exemplified by allopregnanolone [5α-pregnan-3α-ol-20-77 
one; 3α, 5α-tetrahydroprogesterone (3α, 5α-THPROG)], a neuroactive metabolite of 78 
progesterone in the brain (17, 18). 79 
Numerous biochemical studies have established a relationship between the chemical structure 80 
of steroidal ligands and their ability to transactivate PR and AR. Moreover, X-ray crystal 81 
structures of the ligand-binding domain of PR and AR complexed with various ligands have 82 
brought a new insight on the ligand binding mode (19 - 22). Our aim was to characterize the 83 
activity of NES, a progesterone related progestin, and its potent analogue 13-ethyl-NES 84 
derivative (23) on PR and AR and to identify the binding contacts responsible for their increased 85 
potency and those involved in their selectivity. 13-ethyl NES was previously synthesized by 86 
Gedeon Richter (Hungary) to compare its oral bioactivity compared to NES. Here, we used 13-87 
ethyl NES to compare PR and AR binding with that of LNG, also a 13 ethyl substituted, but 19-88 
nortestosterone derivative. 89 
Further to the transactivation studies we conducted NES metabolite profiling in mice to 90 
determine whether NES is metabolized similarly to progesterone and if reduced metabolite(s) of 91 
NES are active on the mouse brain tissue. In this regard, some of the reduced metabolites of 92 
progesterone are established as potent and selective positive allosteric modulators of the γ-93 
aminobutyric acid type A receptor (GABAAR). Upon administration, these steroids exhibit clear 94 
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behavioral effects that include anxiolysis, sedation and analgesia, they are anticonvulsant and 95 
at high doses induce a state of general anesthesia (24, 25). The demonstration that certain 96 
neurons and glial cells within the central nervous system (CNS) can synthesize these steroids 97 
either de novo, or from peripherally derived progesterone, has led to the proposal that these 98 
steroids (neurosteroids) can additionally function in an autocrine, or paracrine manner, to locally 99 
influence GABAergic transmission (26).  100 
Not all progestins exert the same behavioral effects as natural progesterone, possibly due to 101 
lack of conversion into 5α-reduced metabolites, or due to the lack of an interaction with the 102 
GABAAR. We therefore assessed the potential of NES progestin to be metabolized in mouse 103 
brain tissue and using electrophysiology compared the GABAAR modulatory action of one of 104 
these metabolites 3α, 5α-tetrahydronestorone (3α, 5α-THNES) with the progesterone metabolite 105 
3α, 5α-THPROG.  106 
 107 
METHODS  108 
A. STRUCTURE ACTIVITY EXPERIMENTS 109 
AR and PR transactivation by NES, 13-ethyl NES and LNG 110 
The expression vectors pchPR code for human PRB. The human AR expression vector pcDNA-111 
hAR was kindly provided by G.A. Coetzee. The plasmid pcβgal, which contains the β-112 
galactosidase sequence, was used to standardize the transfection experiments. The reporter 113 
vector GRE2Luc was the kind gift from Drs. A. Biola-Vidamment and M. Pallardy. HEK 293T 114 
cells were routinely cultured in a high-glucose DMEM medium (Invitrogene, Cergy Pontoise, 115 
France), 20 mM HEPES, 2 mM glutamine, 1X non-essential amino acids, 100 U/mL penicillin 116 
and 100 µg/mL streptomycin supplemented with 10% fetal calf serum (FCS) in a humidified 117 
atmosphere at 37°C and with 5% CO2. One day before transfection, the cells were seeded at 118 
3x106 cells/80-mm diameter culture Petri dish and cultured overnight in the same medium. Six 119 
hours before transfection, the FCS supplemented medium was replaced by the same medium 120 
supplemented with 10% dextran-charcoal treated FCS. Transfections were carried out using the 121 
calcium phosphate precipitation method. The calcium phosphate precipitate was prepared with 122 
one of the steroid receptor expression vectors (0.5 µg pchPRB or 2 µg pchAR,) plus 7 µg of the 123 
reporter vector GRE2-Luc and 1 µg of pcβgal, in 1 ml of 140-mM NaCl, 0.75 mM Na2HPO4, 25 124 
mM HEPES, 125 mM CaCl2, pH 7.05 and added to the cells 30 minutes later. After incubating 125 
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for 16 h, the transfected cells were washed with PBS containing 2.5 mM EDTA, trypsinized and 126 
pooled. The transfected cells were replated in 24-well plates (100,000 transfected cells/well). 4h 127 
later, ligands (NES, 13-ethyl NES, or LNG at various concentrations) were added to the 128 
transfected cells and the incubation continued for a further 24h at 37°C. Cells were lysed in 300 129 
µl PBS 1X, 25-mM glycylglycine, 4 mM EDTA, 15% glycerol, 1% triton X-100, 15 mM MgSO4, 130 
pH 7.8 supplemented with 2 mM β-mercaptoethanol. The luciferase activities were quantified 131 
using a Mithras LB940 microplate reader (Berthold). To standardize the transfection efficiency, 132 
the relative light units (RLU) obtained in the luciferase assay were divided by the optical density 133 
obtained in the β-galactosidase assay. 134 
 135 
Docking of NES within the ligand-binding pocket of the androgen and progesterone 136 
receptors 137 
NES was build using the build fragment function of the Discovery Studio package (version 3.1, 138 
Accelrys, San Diego, USA). The C17 side chains of NES were oriented to superimpose those of 139 
Ulipristal Acetate (27) After minimization using the charmm27 forcefield, NES was manually 140 
docked within the X-ray crystal structure of the AR and PR LBDs (PDB identification numbers 141 
2AMA and 1A28, respectively) by taking as guides the probe accessible volume of each cavity. 142 
The orientation of the ligand or protein side chains were fixed during the docking process.  143 
 144 
B. METABOLISM STUDIES IN BRAIN 145 
 146 
B.1. CHEMICALS 147 
Nestorone (NES) was synthesized under GMP conditions at Crystal Pharma, Spain. In addition, 148 
reduced metabolites of NES such as: 5α-dihydronestorone (5α-DHNES), 20α-dihydronestorone 149 
(20α-DHNES), 3α, 5α-tetrahydronestorone (3α, 5α-THNES) and 3β, 5α-tetrahydronestorone 150 
(3β, 5α-THNES) were custom synthesized by Crystal Pharma Valladolid Spain based on 151 
structure designs that we intended to explore corresponding to the known progesterone 152 
metabolite(s) potentially interacting with the GABA-A receptor (Fig 1). The structures of 153 
synthetic reference reduced metabolites were confirmed and purity determined to 95-98%. 154 
 155 
B.2. STEROIDS MEASUREMENTS IN MOUSE BRAIN AND PLASMA BY GC/MS/MS 156 
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An acute subcutaneous injection of NES (10 µg/mouse or 200 µg/mouse) was administered to 157 
3-month old C57Bl6 female mice. Mice were sacrificed by decapitation after anesthesia with 158 
isoflurane at 0.5h, 1h and 2h post-administration for low dose experiment and 0.5h, 1h, 2h, 4h 159 
and 24h post-administration for high dose experiment (n=6 per group). Blood samples were 160 
collected, centrifuged at 3000 g for 10 min at 4°C to obtain plasma samples (200-300 µl). The 161 
brain (400 - 500 mg) was dissected out on a bed of crushed ice and weighed. The samples 162 
were stored at -20°C until gas chromatography/mass spectrometry/mass spectrometry 163 
(GC/MS/MS) analysis. 164 
 165 
NES, 5α-DHNES, 20α-DHNES, 3α, 5α-THNES and 3β, 5α-THNES were determined by 166 
GC/MS/MS according to the purification protocol described by Meffre et al (28) with minor 167 
modifications. Extraction was performed by adding 10 volumes of methanol (MeOH) and 168 
internal standards were introduced for steroid quantification: 2 ng [2H6]5α-DHPROG (CDN 169 
Isotopes, Pointe Claire, Canada) for 5α-DHNES, 2 ng [13C3] androstenedione (Isoscience, PA, 170 
USA) for NES and 20α-DHNES and 2 ng of epietiocholanolone for 3α, 5α-THNES and 3β, 5α-171 
THNES. Samples were purified and fractionated by solid-phase extraction with the recycling 172 
procedure (29). The unconjugated steroids-containing fraction was filtered and further purified 173 
and fractionated by HPLC. The HPLC system is composed of a WPS-3000SL analytical 174 
autosampler and a LPG-3400SD quaternary pump gradient coupled with a SR-3000 fraction 175 
collector (Thermoscientific, USA). The HPLC separation was achieved with a Lichrosorb Diol 176 
column (25 cm, 4.6 mm, 5 µm) in a thermostated block at 30°C. The column was equilibrated in 177 
a solvent system of 90% hexane and 10% of a mixture composed of hexane/isopropanol 178 
(85/15). Elution was performed at a flow-rate of 1 ml/min, first with 90% hexane and 10% of 179 
hexane/isopropanol (85/15) for 8 min, then with a linear gradient to 100% of hexane/isopropanol 180 
(85/15) in 2 min. This mobile phase was kept constant for 10 min and a linear gradient to 100% 181 
MeOH was applied. The column was washed with MeOH for 15 min. The fraction containing 5α-182 
DHNES was collected in the time range 4-15 min. and then derivatized with 50 µl de 183 
MSTFA/NH4I/DTE (1000/2/5) for 1h at 80°C. NES, 20α-DHNES, 3α, 5α-THNES and 3β, 5α-184 
THNES were collected in the time range 15-28 min. and were derivatized with 25 µl 185 
heptafluorobutyric anhydride and 25 µl anhydrous acetonitrile for 1h at 80°C. 186 
 187 
Brain and plasma extracts were analyzed by GC/MS/MS with an AI 1310 autosampler 188 
(Thermoscientific, USA). The Trace 1310 gas chromatograph is coupled with a TSQ 8000 mass 189 
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spectrometer (Thermoscientific, USA). The mass spectrometer was used in tandem mode using 190 
Argon as collision gas. Injection was performed in the split-less mode at 250°C (1 min of split-191 
less time) and the temperature of the gas chromatograph oven was initially maintained at 50°C 192 
for 1 min and ramped between 50 to 200°C at 20°C/min, then ramped up to 300°C at 10°C/min 193 
and finally ramped to 350°C at 30°C/min. The helium carrier gas flow was maintained constant 194 
at 1 ml/min during the analysis. The transfer line and ionization chamber temperatures were 195 
330°C and 200°C, respectively. Electron impact ionization was used for mass spectrometry with 196 
ionization energy of 70 eV. GC/MS/MS signals were evaluated using a computer workstation by 197 
means of the software Excalibur®, release 3.0 (Thermoscientific, USA). Identification of steroids 198 
was supported by their retention time and according to two or three transitions. Quantification 199 
was performed according to the more abundant transition for the calibration solutions and for 200 
the biological extracts. The GC/MS/MS parameters for identification and quantification of NES 201 
and its metabolites are summarized in Table 1 in the supplemental information.  202 
 203 
The evaluation of the analytical procedure included the limit of detection, sensitivity, linearity 204 
and intra- and inter-assay precision. The limit of detection was determined as the lowest amount 205 
of compounds that can be measured by GC/MS/MS with a signal-to-noise ratio greater than 3. It 206 
ranged from 1 pg for NES and 20-DHNES to 10 pg for 5-DHNES, 3, 5-THNES and 3, 5-207 
THNES (see Table 1 in the supplemental information). Method sensitivity was evaluated by 208 
analysing extracts of 100 mg of mouse brain and of 200 µl of mouse plasma containing 209 
progressively lower concentrations of NES and its metabolites down to 0.01 ng/g or 0.01 ng/ml. 210 
The sensitivity was 0.1 ng/g or 0.1 ng/ml for NES and 20-DHNES and 1 ng/g or 1 ng/ml for 5-211 
DHNES, 3, 5-THNES and 3, 5-THNES. Linearity was determined by analysing mice brain 212 
samples prepared at concentrations of 0.01, 0.1, 1 and 10 ng/g of NES and its reduced 213 
metabolites. The assay was linear in this concentration range with a coefficient of correlation of 214 
0.995. Intra-assay precision was determined by analysing 3 replicates per run of 100 mg of mice 215 
brain supplemented with 1, 10 and 100 ng/g of NES and its metabolites. Inter-assay precision 216 
was determined by analysing these samples for a 4-day period. The intra-assay coefficients of 217 
variation were 9.3 - 12.5%, 5.6 - 8.3% and 4.5 - 5.6% and inter-assay coefficients of variation 218 
were 10.1 - 13.2%, 7.2 - 9.4% and 4.8 - 6.5% for 1, 10 and 100 ng/g of NES and its metabolites, 219 
respectively. 220 
 221 
B.3. PR TRANSACTIVATION BY NES AND ITS REDUCED METABOLITES 222 
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Test compounds (NES and its metabolites) were prepared in DMSO. Diluted stock solutions 223 
were stored at 4°C. Human PR, in the test system described below, was challenged with eight 224 
concentrations of NES starting at 100 nM and continuing with 1:5 serial dilutions, and 5α 225 
DHNES, and 3α, 5α THNES, starting at 10,000 nM and continuing with 1:5 serial dilutions.  226 
The nuclear receptor assay system for this transactivation experiment utilized proprietary 227 
human cells engineered to provide constitutive, high-level expression of the full-length human 228 
Progesterone Receptor (hPR). Reporter Assay System 96-well Format Assays Product # 229 
IB05001 (Indigo Biosciences, PA, USA). The reporter vector used in these studies comprise the 230 
firefly luciferase gene functionally linked to an upstream PR response element. 231 
A suspension of Reporter Cells was prepared in Cell Recovery Medium (CRM; containing 10% 232 
charcoal stripped FBS). For PR agonist activity assay, 100 µl of the Reporter Cell suspension 233 
was dispensed into wells of a white, cell culture treated, 96-well assay plate. Immediately prior 234 
to assay setup, test compounds were diluted using compound screening medium (CSM; 235 
containing 10% charcoal stripped FBS) to generate 2x-concentration treatment media. 100 µl of 236 
each treatment medium was dispensed into triplicate assay wells pre-dispensed with Reporter 237 
Cells. Assay plates were incubated at 37°C for 24 hr.  Following the 24 hr incubation period, 238 
treatment media were discarded and 100 μl/well of Luciferase Detection Reagent was added. 239 
Relative light units (RLUs) were quantified from each assay well to determine PR agonist 240 
activity. The performance of PR agonist assays was validated by performing a Reference 241 
Agonist (Progesterone) dose response curve. 242 
 243 
B.4. INTERACTION OF REDUCED NES METABOLITES WITH GABAA RECEPTORS 244 
 245 
Chemicals and reagents for electrophysiological studies of WSS-1 cell and mouse 246 
cortical neurons. 247 
GABA (γ-aminobutyric acid), tetrodotoxin and strychnine (Sigma/Tocris), kyneurenic acid 248 
(Ascent). The neurosteroid 3α, 5α-THPROG was a gift from Dr. Kelvin Gee. The Nestorone 249 
metabolite 3α, 5α-THNES was synthesised by Crystal Pharma Valladolid Spain based on 250 
structure designs supplied by the Population Council. Stock solutions of 3α, 5α-THPROG and 251 
3α, 5α-THNES, in DMSO, were diluted to achieve a final DMSO concentration of ≤ 0.01%. Note 252 
the vehicle had no effect on the GABA-evoked currents recorded from WSS-1 cells, or on the 253 
miniature inhibitory postsynaptic currents (mIPSCs) recorded from mouse cortical neurons. 254 
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 255 
Cell culture and maintenance of WSS-1 cells 256 
WSS-1 cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented 257 
with 10% foetal bovine serum, 1% penicillin/streptomycin and 400 µg/ml geneticin (G-418) used 258 
to positively select cells that express GABAARs. Resistance to the antibiotic is conferred by the 259 
vector containing a cDNA encoding the α1 subunit (30 - 31). The cells were incubated at 37°C 260 
with 5% CO2 atmosphere and re-seeded into a T25 flask every 3 days i.e. when the cells were 261 
80 - 95% confluent. For experiments, 20 - 50μl of solution containing WSS-1 cells were plated 262 
onto a 35mm cell culture dish. Such cells were used 17 - 96 hr. following plating for 263 
electrophysiological experiments. All reagents used were obtained from Invitrogen. 264 
 265 
Electrophysiological studies on WSS-1 cells 266 
Electrophysiological studies were performed using the whole-cell voltage-clamp technique. 267 
WSS-1 cells were voltage-clamped at -60mV using an Axopatch 200B amplifier, low pass 268 
filtered with a cut-off frequency of 2 kHz. The data were recorded and digitized using a Digidata 269 
1440A interface (Axon Instruments, Union City, CA). Data were acquired at 10 kHz and saved 270 
onto a PC hard drive. Currents were analysed using pCLAMP 10.1.3 software (Axon 271 
instruments). Cells were continually superfused (5ml min-1) with an extracellular solution 272 
containing (in mM) NaCl, 140; KCl. 4.7; MgCl2, 1.2; CaCl2, 2.5; glucose, 10; and HEPES, 10 (pH 273 
7.4 with 1M NaOH). Patch pipettes were pulled from 1.5 mm borosilicate glass capillaries with a 274 
micropipette puller (P-87, Sutter Instruments). Each microelectrode was fire polished and had a 275 
final resistance of 1 - 3MΩ when filled with an electrode solution containing (in mM): CsCl, 140; 276 
MgCl2, 2.0; EGTA, 11; ATP (Mg2+ salt) 3; and HEPES, 10 (pH 7.4 with 1M CsOH). With these 277 
intracellular and extracellular solutions the chloride equilibrium potential was approximately 0 278 
mV. GABA and steroids were rapidly applied for 5 sec. (solution exchange time of 15 - 17ms) 279 
using a three-barrel Perfusion Fast-Step (SF-77B) solution exchange system (Warner 280 
Instruments, Hamden, CT, USA). Solution flow was regulated at 0.3 ml min-1 by a syringe pump 281 
(Cole-Parmer, Vernon Hills, IL, USA). Upon establishment of the whole-cell recording mode, 282 
cells were lifted by movement of the recording electrode via the micromanipulator from the base 283 
of the dish and positioned within the stream of the control extracellular recording solution. To 284 
deliver GABA, or GABA + the steroid, the perfusion barrels were stepped rapidly from side to 285 
side, exposing the cell to the test drug solution for 5 sec. Solution exchanges for each cell were 286 
repeated for 4 trials. Experiments were performed at room temperature (20 - 24°C). All reagents 287 
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used were obtained from Sigma-Aldrich Co. All data are expressed as the arithmetic mean ± 288 
S.E.M. Statistical significance of mean data was evaluated using a paired Student's t-test. 289 
  290 
Preparation of murine brain slices for electrophysiology  291 
The methods were essentially as recently described (32). All rodent studies were approved by 292 
the University of Dundee Ethical Review Committee (Home Office Project Licenses 60/4005 and 293 
70/8161, Dr. Belelli), and complied with Schedule 1 of the UK Government Animals (Scientific 294 
Procedures) Act, 1986. Cortical slices were prepared from postnatal day (P) P20 - 24 C57/Bl6 295 
129 SVJ mice of either sex. Mice were killed by cervical dislocation, the brain dissected and 296 
placed in ice-cold oxygenated (95% O2/5%CO2) artificial cerebrospinal fluid (aCSF) containing 297 
(in mM): 225 sucrose, 2.95 KCl, 1.25 NaH2PO4, 26 NaHCO3, 0.5 CaCl2, 10 MgSO4, 10 glucose, 298 
(pH 7.4; 328-330 mosmol l-1). Coronal brain slices were cut to 300 - 350 μm thickness, using a 299 
Vibratome series 1000 PLUS Sectioning System (Intracell, Royston, Hertfordshire, UK) and 300 
then immediately transferred to a nylon mesh platform housed within a chamber containing 301 
circulating oxygenated extracellular solution (ECS, in mM: 126 NaCl, 26 NaHCO3, 2.95 KCl, 302 
1.25 NaH2PO4, 2 MgCl2, 2 CaCl2, 10 glucose [306-309 mOsm]). Such slices remained at room 303 
temperature for a minimum of 1 hr before electrophysiological recording. 304 
 305 
Voltage-clamp recording  306 
During recording, cortical slices were perfused (3 - 5 ml min-1) with ECS maintained at 35 °C, 307 
which was recycled to a 50 ml oxygenated reservoir. For whole-cell recordings, an intracellular 308 
solution (ICS) containing (in mM): 135 CsCl, 10 HEPES, 10 EGTA, 2 MgCl2, 1 CaCl2, 2 Mg-ATP 309 
and 5 QX-314 (pH 7.2-7.3, 290-300 mOsm) was employed. Patch pipettes were made from 310 
thick-walled borosilicate glass (0.95 mm I.D. 1.55 mm E.D. Garner Glass Co. Claremont, CA), 311 
using a PC-10 electrode puller (Narashige, Japan). When filled with ICS, such pipettes had an 312 
open tip resistance of 2 - 6 MΩ. Neurons were visually identified with an upright Olympus 313 
BX50WI microscope (Olympus, Southall, UK) equipped with IR-DIC optics. Pyramidal neurons 314 
located within cortical L II/III were identified based on their canonical pyramidal morphology. 315 
Neurons were voltage-clamped (Vh = -60 mV) using an Axopatch 1D amplifier (Molecular 316 
Devices, CA, USA) and filtered at 2 kHz. The GABAAR-mediated mIPSCs were isolated by 317 
supplementing the ECS with kynurenic acid (2 mM), tetrodotoxin (TTX, 500 nM) and strychnine 318 
(1 M). Data was acquired and digitised (10 kHz) using a NIDAQ mx card (National Instruments, 319 
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TX, USA) and stored directly to PC using WinEDR software (Strathclyde University, UK). Series 320 
resistance compensation was applied up to 80%.  321 
 322 
Analysis of mIPSCs (33)  323 
Digitized data was analyzed offline using WinEDR/WinWCP software (Strathclyde University, 324 
UK). The mIPSCs were identified by an algorithmic detection protocol, then visually inspected 325 
and spurious events omitted. To eliminate distal events, Gaussian distributions of 10 - 90% rise 326 
times were generated and mIPSCs falling outside the Gaussian limits were excluded. For each 327 
neuron, 50 or more mIPSCs were analyzed to determine their peak amplitude, 10 - 90 % rise 328 
time. Accepted mIPSCs recorded from a single neuron were averaged and fitted with either a 329 
mono-exponential (y(t) = Ae(-t/)), or a bi-exponential (y(t) = A1e(-t/) + A2e(-t/)) decay function, 330 
where y(t) is the current amplitude at time t, A is the current amplitude and  is the decay time 331 
constant. To compare goodness of fit between a mono- or bi-exponential decay, an F test was 332 
applied to the standard deviation of the residuals. The mIPSC decay times were best fit by a bi-333 
exponential function. Therefore, a mean weighted decay constant (w) was calculated to 334 
accommodate the relative contribution of each decay component whereby: w = 1P1+2P2. Here, 335 
1 and 2 are the decay time constants for the first and second exponential functions, and P1 and 336 
P2 are the proportions of current amplitude described by each component i.e. 337 
 338 
   339 
 340 
Data are expressed as mean values ± standard error of the mean (S.E.M.). To determine 341 
statistical significance a one way ANOVA followed post-hoc by Tukey’s HSD test (SPSS 342 
software, Chicago, IL, USA) was performed. 343 
 344 
RESULTS 345 
 346 
NES STRUCTURE ACTIVITY RELATIONSHIPS 347 
Transactivation Studies  348 
Transactivation assays performed in HEK293T cells transiently expressing PR revealed that 349 
NES and 13-ethyl NES display the same potency to activate PR (EC50: 8.2 pM; Fig.2A). These 350 
two molecules are much more potent than progesterone (EC50: 98 pM; Fig. 2A) and 351 
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norethindrone (EC50: 53 pM; Fig. 2A), a testosterone derived progestin characterized by a 13-352 
methyl group. Interestingly, NES and 13-ethyl NES are nearly as potent as LNG, a testosterone 353 
derived progestin characterized by a 13-ethyl group substitution (EC50: 5.8 pM; Fig.2A). These 354 
results show that the replacement of a methyl group by an ethyl group at the C13 position does 355 
not modify the already high potency of NES, whereas it increases that of norethindrone. 356 
Transactivation assays performed in HEK293T cells transiently expressing AR revealed that 357 
NES and 13-ethyl NES are nearly unable to activate AR (Fig.2B), in contrast to LNG which is a 358 
potent AR agonist (EC50: 1.18 ± 0.01 x 10-10 M; Fig. 2B). These results show that the ability of 359 
progestin to activate AR is greatly ensured by the C17 substituents. The 17β-hydroxyl and 17α-360 
ethynyl groups of LNG are much more efficient than the 17β-methylketone and 17α-acetoxy 361 
groups of NES for producing an androgenic response.  362 
NES binding mode to PR and AR LBD 363 
To link the high potency of NES to activate the PR on its chemical structure, we followed a 364 
modeling approach based on the X-ray crystal structure of the PR ligand-binding domain (LBD) 365 
complexed with progesterone (19). Within the ligand-binding cavity of PR NES can adopt the 366 
same positioning as progesterone. The C3 ketone function of NES can be hydrogen bonded to 367 
the Gln725 (3.0 Å) and Arg766 (1.7 Å) (Fig. 3A) and its 17β-methylketone can be anchored to 368 
Cys891 through a CHO hydrogen bond (2.8 Å) (Fig. 3A) as is observed for progesterone (19). 369 
The main difference between NES and progesterone is the presence of the 17α-acetoxy and 370 
16-methylene groups in NES. Both groups can establish additional stabilizing contacts within 371 
the ligand-binding pocket of PR, the 17α-acetoxy group forming van der Waals contacts with 372 
Leu715, Leu718 and Phe794 (Fig.3B) (3.3, 4.4 and 3.2 Å, respectively) and the 16-methylene 373 
group contacting Tyr890 (3.4 Å). These observations may well explain the higher potency of 374 
NES as compared to progesterone. Docking studies of the 13-ethyl NES further revealed that 375 
this molecule adopts the same anchoring positioning in the LBD as NES and that the 13-ethyl 376 
group can be accommodated within the binding pocket at the vicinity of Met909 as the 13-377 
methyl group does (data not shown). This result is in good agreement with the observation that 378 
NES and 13-ethyl NES display the same potency in activating PR. A striking difference was 379 
observed between LNG and norethindrone, since the accommodation of 13-ethyl group of LNG 380 
requires a change in the Met909 orientation permitting additional stabilizing contacts which are 381 
responsible for the higher potency of LNG as compared to norethindrone (22).  382 
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We also used a modeling approach to compare the anchoring mode of NES and LNG within 383 
AR. LNG docking within the X-ray crystal structure of the AR LBD complexed with 384 
dihydrotestosterone (DHT) (PDB ID: 2AMA) reveals that it adopts the same positioning as DHT 385 
and that its C3-ketone function can be hydrogen bonded to the Gln711 and Arg752 and its C17-386 
hydroxyl anchored to Asn705 and Thr877 (data not shown). Docking of NES within the AR LBD 387 
showed that it can also adopt the same orientation as DHT with its C3-ketone function hydrogen 388 
bonded to the Gln711 and Arg752 (3.5 and 2.9 Å) (Fig. 3C). However, NES is unable to be 389 
anchored to Asn705 (Fig. 3C). Furthermore, the 17β-methylketone and 17α-O-acetyl group of 390 
NES make strong unfavorable contacts with Leu701 (2.0 Å), Leu704 (2.7 Å), Asn705 (2.4 Å) 391 
and Met780 (2.9 Å) (Fig. 3D). Thus, NES is not stabilized within the AR binding pocket leading 392 
to an extremely low capacity of this molecule to activate AR. 393 
 394 
METABOLITE PROFILING IN MOUSE BRAIN AND PR TRANSACTIVATION 395 
 396 
Metabolite profiling of NES in mice 397 
 398 
After acute administration of a high dose of NES (200 µg/mouse) in female mice, maximal level 399 
of NES was measured at 1h post-administration both in plasma (4.7 ± 1.1 µg/ml - Fig. 4A) and 400 
brain (0.62 ± 0.09 µg/g - Fig. 4C) with a marked decline to 4h post-administration. GC/MS/MS 401 
analysis revealed that 5α-reduced metabolites of NES such as 5α-DHNES as well as 3α, 5α-402 
THNES and 3β, 5α-THNES were detected both in plasma and brain, but in limited amounts as 403 
compared to NES (Fig 4A, C). 5α-DHNES was the most abundant metabolite in brain at 30 min 404 
post-administration (80.5 ± 25.5 ng/g Fig. 5C) whereas 35α-THNES was the major metabolite 405 
in plasma at 1h post-administration (116.6 ± 26.7 ng/ml - Fig 5A). Maximal levels of 5-DHNES 406 
and 35-THNES were also found in plasma at 1h post-administration (36.3 ± 5.4 and 58.5 ± 407 
17.1 ng/ml, respectively, Fig.5A). 20α-DHNES was not detected. 408 
 409 
In the 2nd experiment, a much lower dose of NES (10 µg/mouse) was administered. Higher 410 
levels of NES were found at 30 min post-administration both in plasma and brain (39.1 ± 5.0 411 
ng/ml and 24.4 ± 2.5 ng/g - Fig. 4B, D) and 5α-DHNES was the only detectable NES metabolite 412 
found at comparable levels relatively to NES in mice brain (11.0 ± 2.2 ng/g - Fig. 4D). High 413 
concentrations of 5α-DHNES were shown in brain (Fig 5D) as compared to the very low levels 414 
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found in plasma (0.13 – 0.19 ng/ml - Fig. 5B). Both THNES (3α, 5α and 3β, 5α) were the major 415 
NES metabolites measured in plasma (1.0 – 1.5 ng/ml - Fig. 5B). 416 
 417 
PR transactivation with NES and its metabolites 418 
 419 
PR agonist activity of NES, 5α-DHNES, 3α, 5α-THNES was evaluated in the human PR 420 
transactivation assay. Based on these results, the putative synthetic NES metabolites possess 421 
significantly lower PR agonist activities as compared to NES, the parent molecule. Progesterone 422 
the reference PR agonist had an EC50 of 650 pM and NES had EC50 value of 24 pM whereas 423 
the EC50 of 5α-DHNES and 3α, 5α-THNES were 410 pM and 2,850 pM respectively.   Compared 424 
to NES, 5α-DHNES, 3α, 5α-THNES were approximately 17x, and 120x, respectively less potent 425 
in activating PR agonist activity. Thus reduction of NES leads to loss of PR activity which may 426 
be due to the lack of strong binding to PR of 5α-DHNES and 3α, 5α-THNES in this assay 427 
system. 428 
 429 
DOES THE NES METABOLITE 3α, 5α-THNES MODULATE GABAARs?  430 
 431 
The reduced metabolite of progesterone; allopregnanolone (3α, 5α-THPROG) is an established 432 
potent positive allosteric modulator of the GABAAR (34 - 36). Indeed, following in vivo 433 
metabolism of progesterone, this steroid enhances GABAAR function and contributes to the 434 
behavioral effects of the parent steroid, progesterone (34). As described above, in the in vivo 435 
study in mice, Nestorone® (NES) was partially converted into 5α-DHNES, 20α-DHNES, 3β, 5α-436 
THNES and 3α, 5α-THNES. Structure activity studies have revealed that progesterone and 5α-437 
DHPROG have little, or no direct effect on the GABAAR (26, 35). By contrast, reduction of the 3-438 
ketone group of 5α-DHPROG, to a 3α-hydroxy (i.e. 3α, 5α-THPROG), confers potent GABAAR 439 
activity (26). Therefore, we investigated whether the equivalent metabolite of Nestorone (3α, 5α-440 
THNES), which crucially incorporates the A ring 3-hydroxy in the α configuration, was similarly 441 
active at the GABAAR. 442 
 443 
Electrophysiological studies on WSS-1 cells 444 
 445 
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Preliminary experiments revealed the rapid application of GABA (10 nM – 1 µM) to WSS-1 cells 446 
expressing α12 GABAARs, (Vh = -60 mV) produced a concentration-dependent inward 447 
current. For all subsequent experiments, a GABA concentration of 3 µM, which gave a response 448 
~ 10% of the maximum response to GABA (EC10) was utilised. The co-application of GABA (3 449 
µM) with 3α, 5α-THPROG (100 nM) produced a large increase of the GABA-evoked response 450 
(461 ± 69% of control; n = 4; p < 0.001 paired Student’s t-test) - Figure 6. Under identical 451 
conditions, the Nestorone metabolite 3α, 5α-THNES (100 nM) produced only a modest, albeit 452 
significant (p < 0.01 Student’s paired t-test), enhancement of the GABA-evoked response (131 ± 453 
4% of control; n = 10 cells) - see Figure 6. Furthermore, an increased concentration of 3α, 5α- 454 
THNES (1µM) did not produce a further increase of the GABA-evoked current and indeed was 455 
now statistically ineffective in this respect (129 ± 13 % of control; n = 5 cells; (p > 0.05; student’s 456 
paired t-test) – see Figure 6. 457 
  458 
Electrophysiological studies on mouse cortical neurons 459 
 460 
The GABAARs engineered to be expressed in a cell line may not accurately represent the 461 
properties of native neuronal GABAARs. We therefore investigated whether 3α, 5α-THNES may 462 
influence the function of synaptic GABAARs of mouse cortical pyramidal neurons. We have 463 
previously demonstrated that the duration of miniature inhibitory postsynaptic currents (mIPSCs) 464 
mediated by GABA activation of synaptic GABAARs is prolonged by 3α, 5α-THPROG (32). Due 465 
to issues associated with poor penetration of the steroid into the mouse brain slice preparation 466 
we incubated the slice for 2 hr in 3α, 5α-THNES (100 nM, or 1µM). However, under these 467 
conditions, the steroid had no effect at either concentration on the mIPSC decay time – see 468 
Figure 6; Table 1. By contrast, equivalent treatment with 3α, 5α-THPROG (100 nM), produced a 469 
large prolongation of the mIPSC decay time (Figure 6) see (32). See also Table 2 in 470 
supplemental information)  471 
 472 
DISCUSSION 473 
Nestorone is a new chemical entity (NCE) used as a progestin component in female and male 474 
contraceptive methods (8 - 11). It was shown to exert additional non-contraceptive effects that 475 
may lead to health benefits (12 – 16). Previously we showed that NES binds to PR with much 476 
greater affinity than P, but does not bind to AR. These in vitro results were also confirmed by 477 
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bioassays in in vivo animal models (3). Our previous results showed the high selectivity of NES 478 
in terms of its high progestational activity without any androgenic or estrogenic activity.  In this 479 
study we show that NES and 13-ethyl NES, two progesterone related structures, with a 13-480 
methyl and 13-ethyl substituent respectively, display the same high potency to activate the 481 
human PR. In contrast, LNG, a 19-nortestosterone-related progestin with a 13-ethyl substituent 482 
was shown to be much more potent than norethindrone, the corresponding testosterone-related 483 
progestin with a 13-methyl substituent (22). Accordingly, NES and 13-ethyl NES are 484 
accommodated in the ligand-binding cavity of PR in a similar mode, creating the same network 485 
of stabilizing contacts, as revealed by docking studies. In contrast, the binding mode of LNG 486 
and norethindrone to the human PR are quite distinct. Thus, the replacement of a methyl group 487 
by an ethyl does not modify the activity of progesterone-related progestins, although it increases 488 
the activity of testosterone-related progestin structures. 489 
In addition, in this structure activity relationship study, we showed that the ethylene radical in 490 
C16 position for both NES and 13-ethyl NES creates an additional anchor increasing the potent 491 
progestational action of NES and 13-ethyl NES. In contrast to LNG, NES did not bind to the 492 
ligand binding domain of AR and did not transactivate the AR confirming its lack of androgenic 493 
activity previously shown in an in vivo bioassay (3). The differential action of NES on PR and AR 494 
was also confirmed by Attardi et al (37) using other in vivo models. 495 
 496 
In several earlier studies, neuroregenerative and neuroprotective effects of NES were observed 497 
in a stroke model (13, 14) and remyelination effects of NES were observed in a cuprizone 498 
demyelinated mice model (14, 15). These findings were shown to be PR related as the effects 499 
were not observed in knock-out mice models (14). In our earlier pharmacology studies, we did 500 
not investigate if NES converts to reduced metabolites comparable to metabolites formed with 501 
progesterone, specifically 3α, 5α-THPROG, a potent neurosteroid (allopregnanolone) with 502 
neuroprotective effects (17, 18). Therefore, we assessed whether NES would convert into 503 
reduced metabolites in mouse plasma and brain tissue at different time periods following NES 504 
subcutaneous administration of low and high NES dose. The low dose (equivalent to a 505 
neuroprotective dose in mice) and high dose (pharmacological) of NES was chosen so as to 506 
show the potential for NES conversion to dihydro and tetrahydro-NES (equivalent to 507 
allopregnanolone formation with progesterone) metabolites using GC/MS/MS method. The high 508 
dose was used in these experiments to make sure that the reduced metabolites are detected by 509 
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GC/MS/MS with a sufficient sensitivity. The metabolites were identified and quantified by 510 
sensitive and specific GC/MS/MS method using synthetic reference standards (28, 29).  We 511 
demonstrated the presence of reduced NES metabolites in both brain tissue and plasma when 512 
NES is injected in mice subcutaneously. However the concentrations of reduced metabolites 513 
detected in brain and plasma appeared to be much lower than the concentration of reduced 514 
metabolites obtained with progesterone. 515 
 516 
The 5α-DHNES was converted to 3α, 5α-THNES in the brain from mice treated with a high dose 517 
of NES which is similar to the formation of 3α, 5α-THPROG (allopregnanolone) from 5α–518 
DHPROG, but at a much lower conversion rate. Indeed, the concentration of 3α, 5α-THNES in 519 
the brain tissue samples was very low compared to NES and 5α-DHNES levels in brain tissue 520 
samples. In mice injected with a low dose of NES, the 3α, 5α-THNES metabolite was 521 
undetectable in brain tissue. Only 5α-DHNES was detectable following injection of the low dose 522 
of NES. The high concentration of 5α-DHNES found in the brain as compared to the very low 523 
levels found in plasma clearly indicate a high 5α-reductase activity in brain.  524 
 525 
Dense expression of the 5α-reductase enzyme in the white matter has been well demonstrated 526 
(38). An active 5α-reductase activity has also been shown to be present in peripheral 527 
myelinated nerves (39). The localization in myelin membranes may suggest a possible 528 
involvement of 5α-reduced metabolites of the different steroids in the process of myelination. 529 
However, the major metabolite observed with the low dose of 10 µg/animal (therapeutic dose in 530 
demyelination and stroke models) was the 5α-dihydro NES which would not be expected to 531 
interact with the GABAAR, given the presence of keto but not the hydroxyl function at the critical 532 
3 position of the steroid A ring (26). 533 
 534 
We investigated whether these reduced metabolites may have potent activity on the PR 535 
transactivation and if they modulate the function of the GABAAR i.e. in common with 536 
progesterone could they act as neuroprotective in the brain. We tested the bioactivity of reduced 537 
metabolites compared to NES in the PR transactivation assay. NES was very potent in 538 
transactivation of PR, followed by 5α-DHNES, and 3α, 5α-THNES. These findings suggest that 539 
5α-DHNES does bind to PR with a binding affinity sufficient to transactivate PR but was almost 540 
17 times less potent than the parent NES in this transactivation. These observations suggested 541 
that NES is metabolized in the brain by reductive pathway but the overall metabolite 542 
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concentrations may not be enough for GABAA-R receptor activation. This finding leads to our 543 
conclusion that most neurotropic activities of NES relate to the parent molecule and not to its 544 
metabolites. 545 
 546 
While allopregnanolone interacts with the GABAAR and via this interaction is responsible for 547 
certain behaviors produced by progesterone such as sedation, the small conversion of NES into 548 
3α, 5α-THNES and its limited interaction with the GABAAR supports the clinical findings of a lack 549 
of such adverse events with NES at contraceptive doses (10). In rat studies, evaluating the 550 
behavioral profiles indicative of positive allosteric modulation of the GABAAR modulatory 551 
activity, another progestin of the same class of 19-norprogesterone structure, trimegestone 552 
(TMG) was shown to be less active on this likely undesirable endpoint than progesterone and 553 
norethindrone acetate, which may translate into fewer mood-related side effects (40). However 554 
the authors did not assess the metabolites of TMG in brain tissue in these studies. 555 
 556 
In conclusion, we show here for the first time that NES has strong docking and binding 557 
interactions with the ligand binding domain of PR receptor but not AR based on the structure 558 
activity relationship studies. The binding and transactivation properties of NES in regard to the 559 
PR and AR structures confirm the potent selective progestational activity of NES in vivo, as well 560 
as its lack of androgenic effect.  561 
In addition, we identified the metabolites of NES produced in the brain tissue and plasma from 562 
mice treated with NES and demonstrated that the 3α-hydroxy ring A reduced metabolite of NES 563 
exhibit little or no enhancement of GABAAR activity. These results support the conclusion that 564 
the beneficial effects of NES on the brain are not related to its metabolite(s) but mainly via its 565 
direct high affinity binding to PR. 566 
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Figure legends 
Figure 1. Structures of Nestorone and its tentative metabolites identified by in vitro metabolism 
studies. Reference metabolites were custom synthesized and used for metabolite profiling, PR 
transactivation and GABAA receptor binding studies 
Figure 2. PR and AR transactivation activity in response to progestins. HEK-293T cells 
transiently expressing the human PR (A) or AR (B) were incubated for 16 h with progesterone 
(Prog), levonorgestrel (Levo), Nestorone (NES), 13 ethyl Nestorone (13NES) or Norethindrone 
(Noret).The cell extracts were assayed for luciferase and β-galactosidase activities. The PR and 
AR transactivation activity was determined by the luciferase activity normalized by the β-
galactosidase activity. Values are the means ± SEM of three independent experiments performed 
in triplicate. The GraphPad Prism software was used for curve fitting and calculation of the EC50 
values. 
Figure 3. Docking of Nestorone within the PR and AR ligand-binding cavity. The 
accommodation mode of Nestorone within the PR LBD (PDB ID: 1A28) is shown in 3A and 3B. 
The α-helices of the PR LBD are depicted as grey ribbons. Nestorone accommodation within the 
AR LBD (PDB ID: 2AMA) is presented in 3C and 3D. The α-helices of the AR LBD are depicted 
as blue ribbons. Some residues in the binding pockets are shown with their carbon, oxygen,  
nitrogen and sulfur atoms colored in gray, red, blue and green respectively. The carbon and 
oxygen atoms of the ligand Nestorone are colored in gold and red respectively. The figure panels 
were generated using the Dino package (DINO: Visualizing Structural Biology 2002) 
(http://www.dino3d.org). The view in the B panel (and D) was obtained by applying 90° rotations 
(around the x and z axis) on the A view (and C). 
 
Figure 4 – NES metabolism in plasma and brain of female mice after NES administration. NES 
and its metabolites were measured by GC/MS/MS. NES: nestorone; 5α-DHNES: 5α-
dihydronestorone; 20α-DHNES: 20α-dihydronestorone; 3α5α-THNES: 3α5α-
tetrahydronestorone; 3β5α-THNES: 3β5α--tetrahydronestorone. Steroid concentrations are 
measured in plasma after administration of NES at 200 µg (A) and 10 µg (B) and in brain at 200 
µg (C) and 10 µg (D) at different post-administration time points.  Steroid concentrations are 
expressed as ng/ml ± SEM or ng/g ± SEM.  
Figure 5 – NES metabolism in plasma and brain of female mice after NES administration at 10 
and 200µg/mouse. NES metabolites were measured by GC/MS/MS. 5α-DHNES: 5α-
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dihydronestorone; 20α-DHNES: 20α-dihydronestorone; 3α5α-THNES: 3α5α-
tetrahydronestorone; 3β5α-THNES: 3β5α--tetrahydronestorone. Steroid concentrations are 
measured in plasma after administration of NES at 200 µg (A) and 10 µg (B) and in brain at 200 
µg (C) and 10 µg (D) at different post-administration time points.  Steroid concentrations are 
expressed as ng/ml ± SEM or ng/g ± SEM.  
Figure 6: The nestorone metabolite 3α5α-THNES has little effect on GABAARs. A) Illustrated are 
the GABA (3 µM)-induced inward currents recorded from a representative WSS-1 cell in the 
absence (black trace) and presence (grey trace) of the neurosteroid 3α5α-THPROG (100 nM). 
Note the large enhancement of the GABA-evoked response produced by this neurosteroid. B) 
The nestorone metabolite 3α5α-THNES (100 nM) produced only a modest increase in the GABA 
(3µM) – evoked current. C) A bar chart summarizing the effect of 3α5α-THPROG (100 nM; n = 4) 
and 3α5α-THNES (100 nM, n = 10, 1 µM, n = 5) on the peak amplitude of the GABA-evoked 
response. *** = p < 0.001; ** = p < 0.01 (Student’s t-test). D, E). The black traces illustrate 
averaged mIPSCs recorded from representative mouse cortical pyramidal neurons under control 
conditions. Superimposed upon these control recordings are representative mIPSCs recorded 
from cortical neurons obtained from brain slices incubated for ~ 2 hr. in D) 3α5α-THPROG (100 
nM) and E) 3α5α-THNES (100 nM) – grey traces. F) A bar chart summarizing the effect of 3α5α-
THPROG (100 nM; n = 5 neurons) and 3α5α-THNES (100 nM, n = 4 neurons 1 µM, n = 4 neurons) 
on the control (n = 25 neurons) mIPSC decay time (quantified as the τw the weighted time 
constant of decay [ms]). # # # p < 0.001 (one way ANOVA). Note the large prolongation produced 
by 3α5α-THPROG (100 nM), whereas 3α5α-THNES (100 nM) was inert in this respect. The data 
for the control τw and the τw in the presence of 3α5α-THPROG (100 nM) is reproduced from 
Brown et. al., 2016. 
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